NASDAQ:MACK - Merrimack Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $5.57 -0.08 (-1.42 %) (As of 09/21/2018 04:00 PM ET)Previous Close$5.57Today's Range$5.57 - $5.7752-Week Range$4.71 - $15.39Volume92,449 shsAverage Volume42,607 shsMarket Capitalization$75.39 millionP/E Ratio-0.98Dividend YieldN/ABeta2.17 Company ProfileDiscussionAnalyst RatingsChartDividend HistoryEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Merrimack Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on biomarker-defined cancers in the United States. The company's clinical programs include MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive non-small cell lung cancer; and MM-141, a human tetravalent bispecific antibody that is in Phase II clinical trial for treating patients with metastatic pancreatic cancer with high serum levels of free insulin-like growth factor 1. Its clinical program also comprises MM-310, an antibody-directed nanotherapeutic, which is in Phase I clinical trial to solid tumors. In addition, the company is developing preclinical product candidates for various solid tumor indications. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts. Receive MACK News and Ratings via Email Sign-up to receive the latest news and ratings for MACK and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical SymbolNASDAQ:MACK CUSIP59032810 Webwww.merrimackpharma.com Phone617-441-1000 Debt Debt-to-Equity RatioN/A Current Ratio3.45 Quick Ratio3.45 Price-To-Earnings Trailing P/E Ratio-0.98 Forward P/E Ratio-1.54 P/E GrowthN/A Sales & Book Value Annual Sales$144.27 million Price / Sales0.52 Cash FlowN/A Price / CashN/A Book Value$7.22 per share Price / Book0.77 Profitability EPS (Most Recent Fiscal Year)($5.66) Net Income$472.02 million Net MarginsN/A Return on Equity-60.33% Return on Assets-42.77% Miscellaneous Employees72 Outstanding Shares13,340,000Market Cap$75.39 million Merrimack Pharmaceuticals (NASDAQ:MACK) Frequently Asked Questions What is Merrimack Pharmaceuticals' stock symbol? Merrimack Pharmaceuticals trades on the NASDAQ under the ticker symbol "MACK." When did Merrimack Pharmaceuticals' stock split? How did Merrimack Pharmaceuticals' stock split work? Shares of Merrimack Pharmaceuticals reverse split on Wednesday, September 6th 2017. The 1-10 reverse split was announced on Thursday, August 31st 2017. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 5th 2017. An investor that had 100 shares of Merrimack Pharmaceuticals stock prior to the reverse split would have 10 shares after the split. How were Merrimack Pharmaceuticals' earnings last quarter? Merrimack Pharmaceuticals Inc (NASDAQ:MACK) released its quarterly earnings results on Tuesday, August, 7th. The biopharmaceutical company reported ($1.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.28) by $0.05. View Merrimack Pharmaceuticals' Earnings History. When is Merrimack Pharmaceuticals' next earnings date? Merrimack Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November, 14th 2018. View Earnings Estimates for Merrimack Pharmaceuticals. What price target have analysts set for MACK? 2 Wall Street analysts have issued 1 year price objectives for Merrimack Pharmaceuticals' stock. Their forecasts range from $7.00 to $7.00. On average, they anticipate Merrimack Pharmaceuticals' share price to reach $7.00 in the next twelve months. This suggests a possible upside of 25.7% from the stock's current price. View Analyst Price Targets for Merrimack Pharmaceuticals. What is the consensus analysts' recommendation for Merrimack Pharmaceuticals? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merrimack Pharmaceuticals in the last year. There are currently 1 sell rating and 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Merrimack Pharmaceuticals. Who are some of Merrimack Pharmaceuticals' key competitors? Some companies that are related to Merrimack Pharmaceuticals include Acer Therapeutics (ACER), Paratek Pharmaceuticals (PRTK), Aratana Therapeutics (PETX), Mersana Therapeutics (MRSN), Galectin Therapeutics (GALT), CELYAD SA/ADR (CYAD), Corvus Pharmaceuticals (CRVS), Affimed (AFMD), Bellicum Pharmaceuticals (BLCM), Tocagen (TOCA), Kala Pharmaceuticals (KALA), Tyme Technologies (TYME), Menlo Therapeutics (MNLO), Ardelyx (ARDX) and Athersys (ATHX). Who are Merrimack Pharmaceuticals' key executives? Merrimack Pharmaceuticals' management team includes the folowing people: Dr. Richard Peters, Pres, CEO & Director (Age 55)Ms. Jean M. Franchi, CFO & Treasurer (Age 52)Mr. Jeffrey A. Munsie, Gen. Counsel, Head of Corp. Operations & Sec. (Age 41)Dr. Daryl C. Drummond Ph.D., Head of Research (Age 49)Dr. Sergio L. Santillana, Chief Medical Officer (Age 55) Who are Merrimack Pharmaceuticals' major shareholders? Merrimack Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Newtyn Management LLC (4.75%), Dimensional Fund Advisors LP (3.51%), Wittenberg Investment Management Inc. (1.90%), BlackRock Inc. (1.89%), Connor Clark & Lunn Investment Management Ltd. (1.31%) and Millennium Management LLC (1.28%). Company insiders that own Merrimack Pharmaceuticals stock include Daryl C Drummond and Ulrik B Nielsen. View Institutional Ownership Trends for Merrimack Pharmaceuticals. Which institutional investors are selling Merrimack Pharmaceuticals stock? MACK stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, BlackRock Inc., Northern Trust Corp, Bank of New York Mellon Corp, Bank of New York Mellon Corp, Schwab Charles Investment Management Inc. and Federated Investors Inc. PA. View Insider Buying and Selling for Merrimack Pharmaceuticals. Which institutional investors are buying Merrimack Pharmaceuticals stock? MACK stock was purchased by a variety of institutional investors in the last quarter, including Newtyn Management LLC, Wittenberg Investment Management Inc., Dimensional Fund Advisors LP, Clearline Capital LP, Paloma Partners Management Co, LMR Partners LLP, Millennium Management LLC and Connor Clark & Lunn Investment Management Ltd.. View Insider Buying and Selling for Merrimack Pharmaceuticals. How do I buy shares of Merrimack Pharmaceuticals? Shares of MACK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Merrimack Pharmaceuticals' stock price today? One share of MACK stock can currently be purchased for approximately $5.57. How big of a company is Merrimack Pharmaceuticals? Merrimack Pharmaceuticals has a market capitalization of $75.39 million and generates $144.27 million in revenue each year. The biopharmaceutical company earns $472.02 million in net income (profit) each year or ($5.66) on an earnings per share basis. Merrimack Pharmaceuticals employs 72 workers across the globe. What is Merrimack Pharmaceuticals' official website? The official website for Merrimack Pharmaceuticals is http://www.merrimackpharma.com. How can I contact Merrimack Pharmaceuticals? Merrimack Pharmaceuticals' mailing address is ONE KENDALL SQUARE SUITE B7201, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-441-1000 or via email at [email protected] MarketBeat Community Rating for Merrimack Pharmaceuticals (NASDAQ MACK)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 298 (Vote Outperform)Underperform Votes: 227 (Vote Underperform)Total Votes: 525MarketBeat's community ratings are surveys of what our community members think about Merrimack Pharmaceuticals and other stocks. Vote "Outperform" if you believe MACK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MACK will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 9/22/2018 by MarketBeat.com StaffFeatured Article: How Do You Calculate Return on Investment (ROI)?